Phase 3 Metaspher Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The safety profile of subcutaneous trastuzumab was consistent with the known profile of intravenous administration of the agent and there were no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer.

Clinical breastEuropean journalNeoadjuvant her2Her2 positive metastatic breast cancerPhase 3 metaspher trial